CD274 and non-small cell lung carcinoma: In order to analyze the prognostic and predictive value of the TRN signature, we used bulk RNA-seq data from pre-treatment tumors from POPLAR79 and OAK,80 two randomized clinical trials of anti-PD-L1 antibody (atezolizumab) versus chemotherapy (docetaxel) in patients with NSCLC, representing the largest transcriptional collection in these settings.81